Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELL | P14151 | 1/20 | 0.46 |
| ▸ | SELP | P16109 | 1/20 | 0.46 |
| ▸ | SELE | P16581 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | APEX1 | P27695 | 1/20 | 0.39 |
| ▸ | MPI | P34949 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
| ▸ | ACLY | P53396 | 3/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12449521 | 0.82 | RAPGEF4 (0.36) | ACHEALDH1A1KMT2AMAPTTSHR | |
| SCHEMBL16929987 | 0.76 | NMT1 (0.35) | ACHEALDH1A1KMT2AMAPTHPGD | |
| SCHEMBL17696925 | 0.75 | TSHR (0.56) | ALDH1A1KMT2AKDM4EPOLBMAPT | |
| SCHEMBL7724614 | 0.75 | HPGD (0.56) | SELLSELPSELEACHEALDH1A1 | |
| SCHEMBL2210414 | 0.75 | SELL (0.57) | SELLSELPSELEACHEALDH1A1 | |
| SCHEMBL8761509 | 0.75 | SELL (0.50) | SELLSELPSELEACHEALDH1A1 | |
| SCHEMBL6841589 | 0.75 | SELL (0.65) | SELLSELPSELEACHEALDH1A1 | |
| SCHEMBL16373692 | 0.75 | RAPGEF4 (0.39) | SELLSELPSELEALDH1A1KMT2A | |
| SCHEMBL13550105 | 0.75 | RAPGEF4 (0.41) | ALDH1A1KMT2AMAPTTSHRLMNA | |
| SCHEMBL17864586 | 0.75 | ACHE (0.65) | SELLSELPSELEACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12466781-B2 | Thyromimetics | AUTOBAHN THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4419532-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-08-28 | — | — | EP | disclosed |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2024-08-22 | — | — | US | disclosed |
| CN-118119626-A | Fused bicyclic heteroaryl compounds useful as NLRP3 inhibitors | 豪夫迈·罗氏有限公司 | 2024-05-31 | — | — | CN | disclosed |
| WO-2023066825-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-04-27 | — | — | WO | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| US-20230048992-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. | 2023-02-16 | — | — | US | disclosed |
| CN-115279359-A | Novel thyromimetic agents | 速通医疗公司 | 2022-11-01 | — | — | CN | disclosed |
| EP-4065098-A1 | NOVEL THYROMIMETICS | Autobahn Therapeutics, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
| WO-2021108549-A1 | NOVEL THYROMIMETICS | AUTOBAHN THERAPEUTICS, INC. (US) | 2021-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230048992-A1 | NOVEL THYROMIMETICS | TSHR, TPO, CHRM1 | SELL 4779/4885SELP 4861/4885SELE 4641/4885 |
| US-12466781-B2 | Thyromimetics | TPO, TSHR, CHRM1 | SELL 4727/4885SELP 4862/4885SELE 4572/4885 |
| US-20240279237-A1 | FUSED BICYCLIC HETEROARYL COMPOUNDS USEFUL AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | SELL 4142/4885SELP 4722/4885SELE 4537/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.